Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2022 16:43 ET | Source: Surface Oncology, Inc.

Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
March 31, 2022 07:30 ET | Source: Surface Oncology, Inc.

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
March 15, 2022 07:30 ET | Source: Surface Oncology, Inc.

Surface Oncology Appoints Theresa Boni as General Counsel

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
March 02, 2022 07:10 ET | Source: Surface Oncology, Inc.

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021

Continued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types Company continues...
February 28, 2022 16:30 ET | Source: Surface Oncology, Inc.

Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
February 10, 2022 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
December 15, 2021 07:05 ET | Source: Surface Oncology, Inc.

Surface Oncology Appoints Denice Torres as Chair of the Board of Directors

Biopharma veteran Ben Hickey appointed to Board of Directors Lisa McGrath promoted to chief people officer; Shannon Devens promoted to senior vice president, development operations CAMBRIDGE, Mass.,...
December 06, 2021 09:30 ET | Source: Surface Oncology, Inc.

Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
December 03, 2021 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Named a 2021 Top Place to Work by the Boston Globe

CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment,...
December 02, 2021 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right